Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). [electronic resource]
Producer: 20021209Description: 916-21 p. digitalISSN:- 0002-9149
- Abciximab
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal -- therapeutic use
- Blood Vessel Prosthesis Implantation
- Coronary Angiography -- adverse effects
- Creatine Kinase -- blood
- Creatine Kinase, MB Form
- Double-Blind Method
- Drug Evaluation
- Endpoint Determination
- Female
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Incidence
- Isoenzymes -- blood
- Male
- Myocardial Ischemia -- epidemiology
- North America -- epidemiology
- Platelet Aggregation Inhibitors -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- therapeutic use
- Stents
- Survival Analysis
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.